Evidence map›Paper›PMID 26516409›Full record

ReviewWorld journal of stem cells2015

Therapies targeting cancer stem cells: Current trends and future challenges.

Denisa L Dragu, Laura G Necula, Coralia Bleotu, Carmen C Diaconu, Mihaela Chivu-Economescu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of stem cells, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

130 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Targeted Cancer Stem Cell Therapeutics: An Update.Current topics in medicinal chemistry · 2025
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Denisa L DraguDenisa L Dragu, Laura G Necula, Coralia Bleotu, Carmen C Diaconu, Mihaela Chivu-Economescu, Cellular and Molecular Department, Stefan S. Nicolau Institute of Virology, 030304 Bucharest, Romania.
Laura G NeculaDenisa L Dragu, Laura G Necula, Coralia Bleotu, Carmen C Diaconu, Mihaela Chivu-Economescu, Cellular and Molecular Department, Stefan S. Nicolau Institute of Virology, 030304 Bucharest, Romania.
Coralia BleotuDenisa L Dragu, Laura G Necula, Coralia Bleotu, Carmen C Diaconu, Mihaela Chivu-Economescu, Cellular and Molecular Department, Stefan S. Nicolau Institute of Virology, 030304 Bucharest, Romania.
Carmen C DiaconuDenisa L Dragu, Laura G Necula, Coralia Bleotu, Carmen C Diaconu, Mihaela Chivu-Economescu, Cellular and Molecular Department, Stefan S. Nicolau Institute of Virology, 030304 Bucharest, Romania.
Mihaela Chivu-EconomescuDenisa L Dragu, Laura G Necula, Coralia Bleotu, Carmen C Diaconu, Mihaela Chivu-Economescu, Cellular and Molecular Department, Stefan S. Nicolau Institute of Virology, 030304 Bucharest, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traditional therapies against cancer, chemo- and radiotherapy, have multiple limitations that lead to treatment failure and cancer recurrence. These limitations are related to systemic and local toxicity, while treatment failure and cancer relapse are due to drug resistance and self-renewal, properties of a small population of tumor cells called cancer stem cells (CSCs). These cells are involved in cancer initiation, maintenance, metastasis and recurrence. Therefore, in order to develop efficient treatments that can induce a long-lasting clinical response preventing tumor relapse it is important to develop drugs that can specifically target and eliminate CSCs. Recent identification of surface markers and understanding of molecular feature associated with CSC phenotype helped with the design of effective treatments. In this review we discuss targeting surface biomarkers, signaling pathways that regulate CSCs self-renewal and differentiation, drug-efflux pumps involved in apoptosis resistance, microenvironmental signals that sustain CSCs growth, manipulation of miRNA expression, and induction of CSCs apoptosis and differentiation, with specific aim to hamper CSCs regeneration and cancer relapse. Some of these agents are under evaluation in preclinical and clinical studies, most of them for using in combination with traditional therapies. The combined therapy using conventional anticancer drugs with CSCs-targeting agents, may offer a promising strategy for management and eradication of different types of cancers.

Indexed as

Anticancer drugsApoptosisBiomarkersCancer stem cellsSignaling pathwaysTargeted therapy

Identifiers

PMID26516409
PMCPMC4620424

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.